SVB Leerink Maintains Market Perform Rating for Myovant Sciences, Lowers Price Target To $12

SVB Leerink has decided to maintain its Market Perform rating of Myovant Sciences MYOV and lower its price target from $19.00 to $12.00.

Shares of Myovant Sciences are trading up 8.08% over the last 24 hours, at $11.23 per share.

A move to $12.00 would account for a 6.86% increase from the current share price.

About Myovant Sciences

Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.